 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| 12345678910111213...858859» |
- | Ibrance (palbociclib) / Pfizer
Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. (Pubmed Central) - Feb 1, 2025
P
Findings from this real-world study indicate patients with HR+/HER2-?ABC treated with palbociclib plus ET maintain their QoL for at least 18
- | Tavneos (avacopan) / Amgen
Journal, Monotherapy: A case of renal limited myeloperoxidase anti-neutrophil cytoplasmic antibody-positive vasculitis treated with maintenance avacopan monotherapy. (Pubmed Central) - Feb 1, 2025
This suggests that the COVID-19 vaccine may have contributed to the development of AAV in this elderly patient. Avacopan monotherapy has been shown to be effective as maintenance therapy to control the progression of renal failure although not sufficient for complete remission of AAV.
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Retrospective data, Review, Journal, Adverse events: Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study. (Pubmed Central) - Feb 1, 2025
Signals indicating occurrence of leukopenia, neutropenia, anemia, and thrombocytopenia were identified for three CDK4/6 inhibitors. Abemaciclib, palbociclib, and ribociclib showed significant but inconsistent hematological toxicity risks.
- ||||| rifampicin / Generic mfg.
New P2 trial: A trial of two host-directed therapies in patients with drug-resistant tuberculosis (DRTB-HDT) (EUDRACT) - Feb 1, 2025
P2, N=330, , Sponsor: The Aurum Institute
- | Parsabiv (etelcalcetide) / Amgen
Journal: Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel. (Pubmed Central) - Jan 31, 2025
Expert consensus was reached on SHPT management, further defining therapeutic strategies and medication use and emphasizing need for treatment early. Despite evidence-based treatment preferences supported by clinical experience, factors other than scientific evidence influence decision making, particularly with medications.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Evolocumab Achieves Low LDL Cholesterol Without Long-Term Cognitive Risks. (Pubmed Central) - Jan 31, 2025
Despite evidence-based treatment preferences supported by clinical experience, factors other than scientific evidence influence decision making, particularly with medications. No abstract available
- | Prolia (denosumab) / Amgen, zoledronic acid / Generic mfg.
Journal: Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass. (Pubmed Central) - Jan 31, 2025
No abstract available Conclusively, both DMAB and ZOL are effective antiresorptive agents that improved BMD over 3
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal, Real-world evidence: Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study. (Pubmed Central) - Jan 31, 2025
Conclusively, both DMAB and ZOL are effective antiresorptive agents that improved BMD over 3 Early romosozumab administration after denosumab withdrawal may control bone turnover rebound and possibly prevent incidence of fractures in post-menopausal osteoporosis.
- || Imlygic (talimogene laherparepvec) / Amgen
P1 data, Journal, Metastases: Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. (Pubmed Central) - Jan 31, 2025
P1
Our findings underscore the feasibility of intratumoral T-VEC administration in advanced PDAC. Further investigation, particularly in combination with immunotherapies administered systemically is warranted to more optimally assess T-VEC in this challenging malignancy.ClinicalTrials.gov Identifier: NCT03086642.
- | Cabometyx (cabozantinib tablet) / Exelixis
Journal, Metastases: A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma. (Pubmed Central) - Jan 31, 2025
A 71-year-old man presented to our hospital for treatment of HCC with chronic hepatitis C. He was refractory to sorafenib, lenvatinib, regorafenib, and ramucirumab and started atezolizumab and bevacizumab therapy in November 2020...The patient did not show disease progression for 11 months without receiving any treatment for HCC. To the best of our knowledge, this is the first report of CR with cabozantinib in advanced HCC.
- | Imjudo (tremelimumab-actl) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Journal, PD(L)-1 Biomarker: A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine. (Pubmed Central) - Jan 31, 2025
We have experienced a case of HCC in the lumbar spine without a primary tumor in the liver. This is a very rare case, and the combination therapy with durvalumab and tremelimumab resulted in a complete response, which we consider to be a valuable case.
- ||| Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion date: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (clinicaltrials.gov) - Jan 31, 2025
P3, N=510, Active, not recruiting, Sponsor: AstraZeneca
This is a very rare case, and the combination therapy with durvalumab and tremelimumab resulted in a complete response, which we consider to be a valuable case. Trial completion date: Dec 2024 --> Dec 2025
- | Stivarga (regorafenib) / Bayer
Observational data, Journal: Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials. (Pubmed Central) - Jan 31, 2025
The amount of non-randomised, single-arm trials in our sample size was concerning, indicating that higher quality research must be conducted. Our results propose that regorafenib's efficacy and safety may be more impactful in cancers other than its FDA approvals.
- || Prolia (denosumab) / Amgen
Review, Journal: Proceedings of the 2024 Santa Fe Bone Symposium: Update on the Management of Osteoporosis and Rare Bone Diseases. (Pubmed Central) - Jan 30, 2025
Topics included an update on clinical uses of osteoanabolic agents, management of patients discontinuing denosumab, bone health optimization for orthopedic surgery, estrogen and testosterone in the management of osteoporosis, osteoporosis treatment in the very old, overview of rare bone diseases, treat-to-target for osteoporosis, and a progress report on global activities of Bone Health ECHO...Ancillary events addressed modern approaches to menopause and bone health, case studies of management of patients at very high fracture risk, and management of patients with rare bone diseases, such as hypophosphatasia, fibrodysplasia ossificans progressiva, X-linked hypophosphatemia, and hypoparathyroidism. These proceedings of the SFBS present the clinical highlights of the plenary sessions and the discussions that followed.
- || Prolia (denosumab) / Amgen
Clinical, Journal: Bone Health ECHO Case Report: Significant Elevation in Bone Turnover Markers and Progression of Vertebral Fractures After Denosumab Discontinuation Followed by a PTH-Analog. (Pubmed Central) - Jan 30, 2025
Here we present the case of a woman with postmenopausal osteoporosis with adverse consequences following discontinuation of denosumab and uncertainties on next steps for management. This case highlights the relevance of selection of the initial bone-targeted medication and the sequence of therapy in osteoporosis management.
- | Prolia (denosumab) / Amgen
Journal: Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate. (Pubmed Central) - Jan 30, 2025
After adjusting for drug discontinuation, Dmab showed an increased risk of VFs within the first two years, contributing to an elevated overall mortality risk. Sensitivity analyses revealed consistent results across different regions.
- | ivabradine / Generic mfg.
Journal: A new stability indicating HPLC method with QDa and PDA detectors for the determination of process and degradation impurities of ivabradine including separation of diastereomeric N-oxides. (Pubmed Central) - Jan 30, 2025
Some additional measurements such as solubility, specific rotation, melting point and differential scanning calorimetry analysis proved the formation of the two diastereomeric N-oxide impurities under oxidative conditions. Method validation was performed according to the International Council for Harmonization guidelines and the analysis of ivabradine, its process related impurities (dehydro ivabradine, acetyl ivabradine, and hydroxy ivabradine) and a major oxidative degradation product (ivabradine N-oxide) was successfully performed by this method.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps. (Pubmed Central) - Jan 30, 2025
P3
Method validation was performed according to the International Council for Harmonization guidelines and the analysis of ivabradine, its process related impurities (dehydro ivabradine, acetyl ivabradine, and hydroxy ivabradine) and a major oxidative degradation product (ivabradine N-oxide) was successfully performed by this method. In patients with severe, uncontrolled asthma and a history of CRSwNP, tezepelumab improved rhinosinusitis symptoms across multiple domains, as well as asthma exacerbations, lung function, asthma control, and health-related quality of life.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Disease activity-guided dose optimisation including discontinuation of TNF-inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study. (Pubmed Central) - Jan 30, 2025
In patients with severe, uncontrolled asthma and a history of CRSwNP, tezepelumab improved rhinosinusitis symptoms across multiple domains, as well as asthma exacerbations, lung function, asthma control, and health-related quality of life. Long-term disease activity-guided dose optimization of TNF inhibitors in RA, including discontinuation and multiple tapering attempts, remains safe and effective.
- | Journal: Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis. (Pubmed Central) - Jan 30, 2025
Long-term disease activity-guided dose optimization of TNF inhibitors in RA, including discontinuation and multiple tapering attempts, remains safe and effective. Our data suggest preference for bDMARDs in the following order: adalimumab/golimumab > infliximab > secukinumab > etanercept (for incident AAU prevention) and adalimumab > golimumab/infliximab/secukinumab > etanercept (for recurrent AAU prevention).
- | Journal: Costimulation blockade: the next generation. (Pubmed Central) - Jan 30, 2025
Investigational agents with subcutaneous delivery methods could overcome logistical challenges, improve adherence, and redefine posttransplant care. These advancements in costimulation blockade may enhance long-term graft survival and transform the management of KT recipients.
- || midodrine hydrochloride / Generic mfg., ivabradine / Generic mfg.
Review, Journal: Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic. (Pubmed Central) - Jan 30, 2025
Particular areas of inquiry include differential efficacy of recommended therapies based on POTS subtypes, and a need for treatments directly targeting the underlying autonomic nervous system dysfunction. PROSPERO, identifier CRD42024505967, https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=505967.
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Case Report: Novel ADA2 variants cause atypical adenosine deaminase 2 deficiency. (Pubmed Central) - Jan 30, 2025
Her condition improved after treatment with etanercept...Fever and hemiplegia were the main manifestations in this patient, without typical rashes. DADA2 was finally confirmed by enzymology and genetic testing, and we believe this is the first reported case of the c.1082-7T>A intronic variant in DADA2, and the RNA studies conducted in this case have been pivotal in assessing its pathogenicity.
- | Prolia (denosumab) / Amgen
Journal: Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis. (Pubmed Central) - Jan 30, 2025
Similarly, in patients with anti-cyclic citrullinated peptide (CCP) antibody positivity or those treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs), although there were significant increases in the T-score and areal BMD at all sites in both groups, there were no significant between-group differences. Our findings suggest that the GC dose considered to increase the risk of GIOP did not significantly attenuate the therapeutic efficacy of denosumab in RA patients, including those positive for anti-CCP antibodies and users of biologic or targeted synthetic DMARDs.
- ||| astegolimab (RG 6149) / Amgen, Roche
Trial completion, Trial completion date, Trial primary completion date: A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects (clinicaltrials.gov) - Jan 30, 2025
P1, N=78, Completed, Sponsor: Genentech, Inc.
Our findings suggest that the GC dose considered to increase the risk of GIOP did not significantly attenuate the therapeutic efficacy of denosumab in RA patients, including those positive for anti-CCP antibodies and users of biologic or targeted synthetic DMARDs. Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Oct 2024 | Trial primary completion date: Apr 2025 --> Oct 2024
- || Imlygic (talimogene laherparepvec) / Amgen
P2 data, Journal: Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial). (Pubmed Central) - Jan 29, 2025
P2
Together, neoadjuvant T-VEC represents a viable treatment option for patients with difficult-to-resect basal cell carcinomas (EudraCT no. 2018-002165-19).
- | Ibrance (palbociclib) / Pfizer
Journal: Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer. (Pubmed Central) - Jan 29, 2025
Knockdown of NSRP1 reduces CDK4/6i (palbociclib) sensitivity of MCF7 cells while overexpression of NSRP1 sensitizes MCF7-PalR cells towards palbociclib treatment...In addition, including NSD2 exon 2 elevates NSD2 protein expression to activate the IFN signaling pathway. This study unveils the critical role of NSRP1 in regulating the IFN signaling pathway and the CDK4/6i resistance, which could be a promising biomarker for predicting therapy response.
- ||| Stivarga (regorafenib) / Bayer
P3 data, Journal, Metastases: INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. (Pubmed Central) - Jan 29, 2025
This study unveils the critical role of NSRP1 in regulating the IFN signaling pathway and the CDK4/6i resistance, which could be a promising biomarker for predicting therapy response. Regorafenib improves survival compared with placebo in refractory AGOC.
- || Clinical, Retrospective data, Review, Journal: Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jan 29, 2025
Dupilumab probably reduced exacerbations more than mepolizumab (RR 0.74 [95% CI 0.62 to 0.89]) (moderate certainty)...Dupilumab is effective at improving patient-relevant outcomes in COPD with higher eosinophil levels. Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes.
- | Journal: Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitor. (Pubmed Central) - Jan 29, 2025
Three major cardiovascular events were noted. These preliminary data, suggest that the mHCVAD-blinatumomab-TKI (mainly ponatinib) regimen may achieve a high rate of CR with undetectable measurable residual disease in adults with R/R Ph+ BCP-ALL and could be proposed to such patients, but cardiovascular or infectious complications should be warning, especially in older or frail patients.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Retrospective data, Journal: Optimizing Granulocyte-Colony Stimulating Factor Dosing Scheme in Healthy Stem Cell Donors for Allogenic Transplantation: A Retrospective Cohort Study of Single Dose vs. Split Dose. (Pubmed Central) - Jan 29, 2025
Donors received daily either a single dose of 10 ?g/kg/day or two doses of 5 ?g/kg/day of filgrastim...Conclusion Split-dose G-CSF administration led to better stem cell mobilization than once-daily dosing. These findings contribute to optimizing G-CSF regimens for allogeneic stem cell donation, potentially improving transplantation outcomes.
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer. (Pubmed Central) - Jan 29, 2025
These findings contribute to optimizing G-CSF regimens for allogeneic stem cell donation, potentially improving transplantation outcomes. No abstract available
- | Praluent (alirocumab) / Sanofi, Regeneron, ezetimibe / Generic mfg., Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Journal: Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on (Pubmed Central) - Jan 29, 2025
No abstract available Subgroup analyses revealed consistent treatment effect amongst comparators vs placebo:
- || volagidemab (REMD-477) / Amgen, REMD Bio
Retrospective data, Review, Journal: Efficacy and safety of the glucagon receptor antagonist volagidemab in type-1 diabetes: A systematic review and meta-analysis. (Pubmed Central) - Jan 29, 2025
Subgroup analyses revealed consistent treatment effect amongst comparators vs placebo: Occurrence of treatment-emergent adverse events (odds ratio [OR]: 0.96 (95% CI: [0.36, 2.56]); I2
- ||| Imdelltra (tarlatamab-dlle) / Amgen
Review, Journal, Adverse events: Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. (Pubmed Central) - Jan 29, 2025
Given that tarlatamab is the first T-cell engager approved for the treatment of small cell lung cancer, raising awareness with regard to the monitoring and management of tarlatamab-associated adverse events is essential. Here, the authors describe the timing, occurrence, and duration of these adverse events and review the management and risk-mitigation strategies used by clinical investigators during the DeLLphi-301 trial.
- | Blincyto (blinatumomab) / Astellas, Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 29, 2025
P1/2, N=36, Recruiting, Sponsor: City of Hope Medical Center
Here, the authors describe the timing, occurrence, and duration of these adverse events and review the management and risk-mitigation strategies used by clinical investigators during the DeLLphi-301 trial. Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Jan 29, 2025
P2, N=47, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
- | Tyvyt (sintilimab) / Eli Lilly, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Enrollment change: Sintilimab Combined with Fruquintinib/Regorafenib (clinicaltrials.gov) - Jan 29, 2025
P2, N=57, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026 N=141 --> 57
- | Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) (clinicaltrials.gov) - Jan 29, 2025
P4, N=82, Recruiting, Sponsor: Natasha Appelman-Dijkstra
N=141 --> 57 Trial completion date: Jun 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027
- || RLY-2608 / Relay Therap
Enrollment change: ReDiscover: First-in-Human Study of Mutant-selective PI3K? Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (clinicaltrials.gov) - Jan 29, 2025
P1, N=890, Recruiting, Sponsor: Relay Therapeutics, Inc.
Trial completion date: Jun 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027 N=400 --> 890
- || Ibrance (palbociclib) / Pfizer, fulvestrant / Generic mfg., Itovebi (inavolisib) / Roche
Review, Journal: Inavolisib: First Approval. (Pubmed Central) - Jan 28, 2025
In the EU and other countries worldwide, regulatory review of inavolisib is currently underway. This article summarises the milestones in the development of inavolisib leading to this first approval for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
- || AZD8630 / AstraZeneca, Amgen
New P1/2 trial: A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma (clinicaltrials.gov) - Jan 28, 2025
P1/2, N=24, Not yet recruiting, Sponsor: AstraZeneca
- || Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Review, Journal: Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review. (Pubmed Central) - Jan 28, 2025
MG generally follows a benign course, in contrast to the more aggressive nature of NMOSD. The utility of biological agents such as inebilizumab for patients with both NMOSD combined with MG warrants further attention.
- || Tepezza (teprotumumab-trbw) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy. (Pubmed Central) - Jan 28, 2025
In addition, some drug candidates and molecular targets identified in the TAO in vitro model have shown promising prospects. This article briefly reviews the potential new strategies for future clinical treatment and the progress of new drug therapies for TAO.
- | Prolia (denosumab) / Amgen, zoledronic acid / Generic mfg.
Retrospective data, Journal: Medication-related osteonecrosis of the jaw in patients with cancer using zoledronic acid and denosumab: Single-center retrospective study. (Pubmed Central) - Jan 28, 2025
The percentage of patients with MRONJ receiving regular dental check-ups was 36.4%, and only 9.1% of patients were aware of MRONJ, both of which are low rates. To reduce MRONJ in patients with cancer, face-to-face consultations with pharmacists could serve as a valuable opportunity to inform patients about MRONJ and encourage regular dental visits.
- || Praluent (alirocumab) / Sanofi, Regeneron, Leqvio (inclisiran) / Novartis, Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Review, Journal: Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Meta-analysis. (Pubmed Central) - Jan 28, 2025
Despite this, the effect on MACE or all-cause death was unclear. Larger-scale randomized controlled trials of longer duration are needed to validate whether this short-term reduction in lipid levels translates into a reduction in clinically meaningful outcomes.
- Imdelltra (tarlatamab-dlle) / Amgen
A Single-Center Experience Initiating Tarlatamab Treatment for Relapsed Extensive-Stage Small Cell Lung Cancer: Navigating Cytokine Release Syndrome () - Jan 28, 2025 - Abstract #IASLCTTLC2025IASLC_TTLC_193;
- Imdelltra (tarlatamab-dlle) / Amgen
Real-World Intracranial and Extracranial Efficacy Plus Safety Analysis of Tarlatamab in Extensive-Stage Small Cell Lung Cancer () - Jan 28, 2025 - Abstract #IASLCTTLC2025IASLC_TTLC_192;
- Imdelltra (tarlatamab-dlle) / Amgen
Real-World Outcomes with Tarlatamab in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer () - Jan 28, 2025 - Abstract #IASLCTTLC2025IASLC_TTLC_170;
- Imdelltra (tarlatamab-dlle) / Amgen
Real-world Experience and Efficacy of Tarlatamab-dlle for Small Cell Lung Cancer in the Second Line Setting and Beyond () - Jan 28, 2025 - Abstract #IASLCTTLC2025IASLC_TTLC_169;